SCHEMBL4831364

SCHEMBL4831364

COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1C(C)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.44
CA9 Q16790 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CYP3A4 P08684 2/20 0.39
HTT P42858 1/20 0.39
CHEK1 O14757 1/20 0.39
DGAT1 O75907 1/20 0.38
LIPG Q9Y5X9 3/20 0.38
LPL P06858 2/20 0.38
HIF1A Q16665 2/20 0.38
P4HB P07237 1/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 2/20 0.37
F2 P00734 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723521 0.88 ALDH1A1 (0.50) CSF1RCA9ALDH1A1KDM4EHSD17B10
SCHEMBL31061615 0.87 CSF1R (0.44) CSF1RCA9KDM4ECA1CA2
SCHEMBL425734 0.87 MKNK1 (0.45) CSF1RCA9ALDH1A1CA1CA2
SCHEMBL2863066 0.87 CSF1R (0.44) CSF1RCA9KDM4ECA1CA2
SCHEMBL20505151 0.85 CYP3A4 (0.49) CA9KDM4ELMNACA1CA2
SCHEMBL5064664 0.82 UCHL1 (0.43) CSF1RCA9ALDH1A1KDM4ELMNA
SCHEMBL28483767 0.82 AAK1 (0.44) CSF1RCA9CA1CA2DGAT1
SCHEMBL1128778 0.82 MAPT (0.48) CSF1RALDH1A1KDM4ELMNAHSD17B10
SCHEMBL21217925 0.81 DGAT1 (0.41) CSF1RCA9ALDH1A1LMNACA1
SCHEMBL21428445 0.81 LMNA (0.42) CSF1RCA9ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963043-B1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2018-05-30 EP disclosed
EP-2963043-B1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2018-05-30 EP disclosed
US-9458176-B2 Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-04 US disclosed
US-9458176-B2 Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-04 US disclosed
US-9458176-B2 Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-04 US disclosed
EP-2963043-A1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2016-01-06 EP disclosed
WO-2014133022-A1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2014-09-04 WO disclosed
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-28 US disclosed
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-28 US disclosed
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-28 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
EP-1513526-B1 PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS SMITHKLINE BEECHAM CORP (US) 2007-11-07 EP disclosed
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators SMITHKLINE BEECHAM CORPORATION 2006-04-27 US disclosed
EP-1513526-A1 PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2005-03-16 EP disclosed
WO-2004000315-A1 PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators LIPA, PNLIP, CEL CSF1R 3332/4885CA9 1429/4885ALDH1A1 903/4885
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative GRM2, GRM1, GRIA2 CSF1R 2151/4885CA9 4262/4885ALDH1A1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.